BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Head and Neck Cancer

6 posts

Head and neck cancer is the second most prevalent type of cancer in the world. It accounts for 6% – 7% of all human cancers, with about 650,000 new cases diagnosed every year. It is one of the deadliest forms of cancer.

The rate of new cases has been increasing rapidly since the beginning of this century. The highest frequency is observed in Eastern Asia and in countries of the North-Atlantic region. The disease affects men more often than women.

The most common site of head and neck cancer is the oral cavity. Throat cancer (carcinoma of the larynx) is the second most common type, followed by cancers of the nasal cavity and paranasal sinuses.

Head and neck cancers arise from different cell types in the head and neck region. The cells that give rise to head and neck cancers can come from any of the following:

– Oral cavity: cancer of the lips, tongue, cheeks, gums, floor of the mouth, or roof of the mouth

– Nasal cavity and paranasal sinuses: cancer of the nose, sinuses, or nasopharynx

– Larynx: cancer of the voice box

– Salivary glands: cancer of the parotid gland, submandibular gland, or sublingual gland.

The cause of head and neck cancer is not fully understood.

RAPT Therapeutics Announces Promising Phase 2 Trial Results for Tivumecirnon

Biotech NewsRAPT Therapeutics Announces Promising Phase 2 Trial Results for Tivumecirnon

  • BioTech Health X
  • April 10, 2024
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced promising results from its Phase 2 clinical trial of Tivumecirnon…
0 Shares
0
0
0
0
0
0
0
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

  • BioTech Health X
  • September 10, 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
0 Shares
0
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • BioTech Health X
  • April 7, 2022
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

  • BioTech Health X
  • September 3, 2021
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
0 Shares
0
0
0
0
0
0
0
Istari Oncology Begins Phase 1 : Phase 2 Sub-Study To Evaluate PVSRIPO in Head and Neck Cancer Patients

Biotech NewsIstari Oncology Begins Phase 1 / Phase 2 Sub-Study To Evaluate PVSRIPO in Head and Neck Cancer Patients

  • BioTech Health X
  • August 17, 2021
Istari Oncology, Inc., a clinical-stage biotechnology firm focused on unique immunotherapy systems for the treatment of strong lumps,…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Lakeside Holding (LSH) Deepens Roots in Pharmaceutical Logistics with $1.5M Sinopharm Agreement
  • NeuBase (NBSE)’s PATrOL™ Platform: The Future of RNA-Targeted Therapies
  • Analysts Maintain Optimism as Lexicon Pharmaceuticals (LXRX) Focuses on Long-Term Growth
  • Mersana (MRSN) Leverages Partnerships with Johnson & Johnson (JNJ), Merck (MRK) to Advance ADCs
  • Aditxt (ADTX)’s $32.7M Investment Fuels Growth in the $84B Autoimmune Disease Market
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • December 17, 2024
    Lakeside Holding (LSH) Deepens Roots in Pharmaceutical Logistics with $1.5M Sinopharm Agreement
    • December 15, 2024
    NeuBase (NBSE)’s PATrOL™ Platform: The Future of RNA-Targeted Therapies
    • December 15, 2024
    Analysts Maintain Optimism as Lexicon Pharmaceuticals (LXRX) Focuses on Long-Term Growth
    • December 14, 2024
    Mersana (MRSN) Leverages Partnerships with Johnson & Johnson (JNJ), Merck (MRK) to Advance ADCs
    • December 12, 2024
    Aditxt (ADTX)’s $32.7M Investment Fuels Growth in the $84B Autoimmune Disease Market
Recent Posts
  • COVID-19 Rocks Yankees, 8th Vaccinated Member to Test Positive - Virology Experts Weigh In
    Corvus (CRVS) Shows Financial Resilience with $41.7M Cash and Strategic R&D Investments
    • December 7, 2024
  • Avidity Biosciences (RNA): Strengthened by $1.6 Billion Cash Position and Strategic Partnerships
    • December 6, 2024
  • The Future of Genomics: GeneDx (WGS) Achieves Profitability & Expands Market Reach
    The Future of Genomics: GeneDx (WGS) Achieves Profitability & Expands Market Reach
    • December 5, 2024
Categories
  • BioTech CEO Interviews (5)
  • Biotech Info (1)
  • Biotech News (96)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top